All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Reported results | 2004-000083-27 | A randomised, parallel-group, double-blind, placebo-controlled Phase III trial assessing the efficacy and safety of ALK Grass Tablet Phleum pratense in subjects with seasonal grass pollen induced rhin... | 2009-11-09 | due-trials |
| No trial status on register, and reported results | 2004-001316-31 | TOLERABILIDAD DE LAS VACUNAS ALERGÉNICAS VALORADAS EN UNIDADES DE MASA Y ADMINISTRADAS POR VÍA SUBLINGUAL. ESTUDIO RANDOMIZADO DOBLE CIEGO CONTROLADO CON PLACEBO EN PACIENTES CON ENFERMEDAD ALÉRGICA R... | bad-data | |
| Reported results | 2004-004924-11 | A multicentre, randomised, double-blind, placebo-controlled parallel group clinical trial to investigate the efficacy and safety of specific sublingual immunotherapy with SLIT One birch in patients wi... | 2006-08-30 | due-trials |
| Reported results | 2005-001573-10 | ESTUDIO DOBLE CIEGO CONTROLADO CON PLACEBO DE INMUNOTERAPIA CON UN EXTRACTO DE Dermatophagoides MEZCLA COMO TRATAMIENTO DEL ASMA PERSISTENTE LEVE-MODERADO Y SU PAPEL AHORRADOR DE MEDICACIÓN DE FONDO | 2009-03-02 | due-trials |
| Reported results | 2005-003460-35 | Evaluación de los cambios inmunológicos tras la inmunoterapia subcutánea con un extracto de Phleum pratense | 2006-07-13 | due-trials |
| Reported results | 2005-004675-37 | Multicenter, randomized, double-blind, placebo-controlled parallel group study to demonstrate the efficacy of a 12-month subcutaneous specific immunotherapy with ALK-depot SQ Milbenmischung in patient... | 2009-05-28 | due-trials |
| Reported results | 2005-004724-39 | A randomised, parallel-group, open, controlled Phase III trial assessing the treatment compliance with GRAZAX in subjects with seasonal grass pollen induced rhinoconjunctiviits | 2007-11-21 | due-trials |
| Reported results | 2005-004731-21 | Estudio doble ciego controlado con placebo para evaluar la eficacia de SLITone en pacientes alérgicos a ácaros de polvo de casa. A randomised, double-blind, placebo-controlled trial assessing the ef... | 2008-12-26 | due-trials |
| Exempt, with results | 2005-004962-18 | A randomised, double-blind, placebo-controlled, multi-centre Phase I Trial investigating the safety of ALK Grass tablet in children aged 5-12 years with grass pollen induced rhinoconjunctivitis (with/... | 2006-05-04 | not-yet-due |
| Exempt, with results | 2005-005402-22 | A randomised, double-blind, placebo-controlled, multi-centre Phase I Trial investigating the safety of GRAZAX-R in children aged 5-12 years with grass pollen induced rhinoconjunctivitis (with/without ... | 2006-04-25 | not-yet-due |
| Reported results | 2005-005636-28 | Valoración de la eficacia a corto plazo de un extracto de Dermatophagoides pteronyssinus, valorado en unidades de masa y administrado por vía subcutánea, en el tratamiento del asma alérgico. Estudio r... | 2008-05-13 | due-trials |
| Reported results | 2006-001795-20 | A phase II-III trial assessing the efficacy and safety of three doses of the ALK HDM tablet in house dust mite allergic subjects. | 2008-07-03 | due-trials |
| Reported results | 2006-003415-46 | A phase III trial investigating the efficacy and safety of Grazax in children aged 5-16 years with grass pollen induced rhinoconjunctivitis with or without asthma | 2007-11-07 | due-trials |
| Completed, but no date, and reported results | 2006-004820-35 | Multicenter, randomized, parallel groups, semi-cross over, open Phase IIIB trial to evaluate treatment compliance for subglossal specific Immunotherapy oral lyophilisate tablets GrazaxR in patients ... | bad-data | |
| Reported results | 2006-005263-26 | A randomised, double-blind, placebo-controlled Phase IIIb Study investigating changes in immunological parameters and cutaneous reactivity induced by a short course immunotherapy with ALK grass tablet... | 2007-08-31 | due-trials |
| Exempt, with results | 2007-000402-67 | Estudio multicéntrico, randomizado, doble ciego-placebo en Fase I para evaluar la seguridad en niños del liofilizado oral ALK de ácaros | 2008-04-01 | not-yet-due |
| Reported results | 2007-000921-23 | A randomised, parallel-group, double-blind, placebo-controlled, multicentre Phase III trial assessing the pharmacodynamic efficacy and safety of an intraseasonal short-time updosing schedule for Aluta... | 2008-10-31 | due-trials |
| Reported results | 2007-006009-26 | A Phase III trial assessing the pharmacodynamic efficacy and the tolerability of Grazax® treatment initiated in the grass pollen season in subjects with seasonal grass pollen induced rhinoconjunctivit... | 2009-02-03 | due-trials |
| Completed, but no date, and reported results | 2008-000196-23 | Efficacy of sublingual immunotherapy with HDM mix extract (Der p and Der f) (SLITone) in pediatric subjects with mild-to-moderate atopic eczema (AE) and sensitization to HDM (SPT positive). | bad-data | |
| Reported results | 2008-003593-18 | A Phase III trial evaluating the tolerability of Grazax treatment in combination with antihistamine in subjects with seasonal grass pollen induced rhinoconjunctivitis | 2009-02-27 | due-trials |
| Reported results | 2008-006921-14 | A multicentre randomised Phase II clinical trial to demonstrate equivalent pharmacodynamic efficacy and tolerability of two updosing schedules for ALK-Flex SQ | 2009-06-19 | due-trials |
| Reported results | 2009-011235-12 | A Randomised,parallel-group,double-blind,placebo-controlled,multi-national,Phase III trial investigating the asthma preventing effect of Grazax compared to placebo in children with grass pollen induce... | 2015-09-30 | due-trials |
| Completed, but no date, and reported results | 2009-011453-41 | Mecanismos moleculares y celulares de rinitis alérgica en pacientes tratados con GRAZAX® -"Molecular and cellular mechanism in rhinitis allergic patients treated with GRAZAX®" | bad-data | |
| Reported results | 2009-014522-41 | An interventional trial assessing the tolerability and safety of GRAZAX® in adults with grass pollen allergy | 2013-07-02 | due-trials |
| Reported results | 2009-014580-39 | A multicentre randomised Phase II clinical pilot study to compare the pharmacodynamic efficacy and tolerability of the sublingual and the vestibular administration route for SLITonePLUS® Birch | 2010-12-21 | due-trials |
| Completed, but no date, and reported results | 2009-014923-22 | A phase IIIB trial investigating 3-year treatment efficacy, tolerability and safety of Grazax in children aged 5-18 years with grass pollen induced rhinoconjunctivitis with/without controlled contro... | bad-data | |
| Reported results | 2010-018621-19 | Efficacy of ALK house dust mite allergy immunotherapy tablet in subjects with house dust mite induced asthma. | 2013-06-25 | due-trials |
| Completed, but no date, and reported results | 2011-000057-23 | Estudio abierto para valorar la tolerabilidad de la inmunoterapia con AVANZ Phleum pratense | bad-data | |
| Reported results | 2011-000120-15 | AVANZ Phleum pratense maintenance dose | 2012-12-21 | due-trials |
| Reported results | 2011-002017-11 | Estudio abierto para evaluar la tolerabilidad de la inmunoterapia con AVANZ Dermatophagoides mezcla | 2012-07-16 | due-trials |
| Reported results | 2011-002277-38 | A one-year trial evaluating the efficacy and safety of the ALK house dust mite allergy immunotherapy tablet in adult subjects with house dust mite allergic rhinitis | 2013-08-04 | due-trials |
| Reported results | 2011-004852-20 | An open trial to assess the tolerability of AVANZ Olive immunotherapy Ensayo abierto para evaluar la tolerabilidad de la inmunoterapia con AVANZ Olivo | 2013-04-12 | due-trials |
| Reported results | 2012-000031-59 | A dose-response evaluation of ALK tree AIT | 2013-09-17 | due-trials |
| Reported results | 2012-002177-62 | A Dose Response Evaluation of SLIToneULTRA HDM Mix Immunotherapy Estudio dosis-respuesta de la inmunoterapia con SLIToneULTRA Dermatophagoides mezcla | 2013-09-04 | due-trials |
| Completed, but no date, and reported results | 2012-005092-14 | Molecular and Cellular Mechanism in the course of Immunotherapy with a Phleum pratense oral lyophilisate Mecanismos moleculares y celulares implicados en la inmunoterapia con un liofilizado oral de... | bad-data | |
| Completed, but no date, and reported results | 2013-001728-20 | An open trial to assess the tolerability of AVANZ® Salsola immunotherapy Ensayo abierto para evaluar la tolerabilidad de la inmunoterapia con AVANZ® Salsola | bad-data | |
| Completed, but no date, and reported results | 2013-004720-11 | An open trial to assess the tolerability of AVANZ® Cupressus immunotherapy Ensayo abierto para evaluar la tolerabilidad de la inmunoterapia con AVANZ® Cupressus | bad-data | |
| Reported results | 2013-005130-38 | Evaluation of the efficacy and safety of AVANZ® Phleum pratense in grass pollen-induced allergic rhinitis during controlled exposure in an environmental challenge chamber | 2015-10-15 | due-trials |
| Reported results | 2015-004821-15 | Efficacy and safety of the SQ tree SLIT-tablet in subjects with moderate to severe allergic rhinitis and/or conjunctivitis induced by pollen from the birch group | 2017-06-20 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2016-004363-39 | A phase III trial evaluating the efficacy and safety of the house dust mite (HDM) sublingual immunotherapy (SLIT)-tablet in children and adolescents (5-17 years) with HDM allergic asthma | 2022-08-10 | bad-data |
| Reported results | 2017-000971-97 | Safety and tolerability of shortened up-dosing with Alutard SQ | 2018-05-29 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2019-000560-22 | A one-year placebo-controlled phase III trial evaluating the efficacy and safety of the house dust mite (HDM) SLIT-tablet in children (5-11 years of age) with HDM allergic rhinitis/rhinoconjunctivitis... | 2023-04-21 | bad-data |
| Reported results | 2020-000446-34 | A 28-day, single-armed, open-label trial to evaluate safety of the house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet in adolescent subjects (12-17 years of age) with HDM allergic rh... | 2021-04-24 | due-trials |
| Completed, reported early | 2020-000455-12 | A randomised, parallel-group, double-blind, placebo-controlled phase III trial assessing the efficacy and safety of 5-grass mix SLIT-drops in adults with grass pollen-induced rhinoconjunctivitis | 2023-12-26 | not-yet-due |
| Reported results | 2020-004372-17 | Efficacy and safety of the SQ tree sublingual immunotherapy tablet in children and adolescents (5 through 17 years of age) with moderate to severe allergic rhinitis and/or conjunctivitis induced by po... | 2023-07-31 | due-trials |